Q-omics provides the consensus-scored BYSL profile across patient tissues and cancer cell-line models. BYSL expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, BYSL is differentially expressed in 16, with the highest sampling consensus in COAD. Additionally, BYSL protein abundance shows 38,424 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRP, COAD, and LSCC as cancer lineages where BYSL shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for BYSL — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes BYSL survival associations across molecular data types. BYSL RNA expression shows survival associations in the most cancer types (27), followed by mutation status (4) and mass-spec protein abundance (12). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible BYSL RNA expression–survival associations across cancer types. High BYSL expression shows unfavorable associations in KIRP, ACC, LIHC, BRCA and LUAD, but favorable associations in SCLC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for BYSL RNA expression.
This table summarizes BYSL tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 13. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for BYSL. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. BYSL shows higher tumor expression in COAD, HNSC, KIRC, LUAD, KIRP and STAD. The COAD box plot shows higher BYSL RNA expression in tumor versus normal tissue (log2 FC = +1.986, t-test p < 0.001).
This table shows molecular features associated with BYSL in patient tissues and cancer cell lines. In patient samples, BYSL shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, BYSL RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and LARGE_INTESTINE.
